Represents the opt-in-fee payable by the entity upon exercise of rights under the collaborative arrangement.

No definition available.

Name:	imgn_CollaborativeAgreementOptInFee
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the amount of potential payments that could be received under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name:	us-gaap_CostOfGoodsSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	imgn_CollaborativeArrangementsAndNoncollaborativeArrangementsTransactionsAxis=imgn_BiotestAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_ExclusiveDevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_PhaseOfClinicalTrialAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_CollaborativeArrangementsProductAxis=imgn_BT062Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_PhaseOfClinicalTrialAxis=imgn_PhaseIibClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements (Details 4) - USD ($)	1 Months Ended		3 Months Ended								12 Months Ended
Agreements (Details 4) - USD ($)	Sep. 30, 2008	Jul. 31, 2006	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Collaborative Agreements disclosures
Costs related to the research and development services			$ 30,437,000	$ 25,666,000	$ 27,647,000	$ 28,018,000	$ 25,787,000	$ 38,280,000	$ 20,862,000	$ 22,029,000	$ 111,768,000	$ 106,958,000	$ 87,073,000
Biotest
Collaborative Agreements disclosures
Costs related to the research and development services											309,000	305,000	339,000
Costs related to clinical materials sold											3,000,000	$ 670,000	$ 577,000
Biotest \| Exclusive license
Collaborative Agreements disclosures
Payments received under collaboration agreement		$ 1,000,000
Opt-in-fee payable on exercise of right			15,000,000								15,000,000
Biotest \| Exclusive license \| Maximum
Collaborative Agreements disclosures
Potential milestone payments		35,500,000
Biotest \| Exclusive license \| Phase I clinical trial \| BT062
Collaborative Agreements disclosures
Payments received under collaboration agreement	$ 500,000
Biotest \| Exclusive license \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments		4,500,000
Biotest \| Exclusive license \| Development milestones \| Phase IIb clinical trial
Collaborative Agreements disclosures
Potential milestone payments			$ 2,000,000								$ 2,000,000
Biotest \| Exclusive license \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments		$ 31,000,000